Bioorganic and Medicinal Chemistry Letters p. 277 - 280 (2003)
Update date:2022-07-30
Topics:
Stelmach, John E.
Liu, Luping
Patel, Sangita B.
Pivnichny, James V.
Scapin, Giovanna
Singh, Suresh
Hop, Cornelis E. C. A.
Wang, Zhen
Strauss, John R.
Cameron, Patricia M.
Nichols, Elizabeth A.
O'Keefe, Stephen J.
O'Neill, Edward A.
Schmatz, Dennis M.
Schwartz, Cheryl D.
Thompson, Chris M.
Zaller, Dennis M.
Doherty, James B.
The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38α MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38α inhibitor reported by Merck Research Laboratories and VX-745. O
View MoreZhuhai Rundu Pharmaceutical co.,Ltd
Contact:+86-756-7630755
Address:No.6,North Airport Road,Sanzao Town,Jinwan District
Shanghai better-in Medical Technology Co.,LTD.
Contact:+86-21-38921049
Address:Lane 720 zhangjianggaoke cailun road, Pudong, Shanghai, room 513
Meryer (Shanghai) Chemical Technology Co., Ltd.
website:http://www.meryer.com/cn/index/
Contact:+86-755-86170518
Address:Minhang,Shanghai, China
Contact:+86-10-59484199
Address:No.58-A1026 Liangguan Street
Contact:86-21-34622192，13917187091，21-34622765
Address:No. 500 Caobao Road Shanghai P.R China
Doi:10.1039/jr9580004113
(1958)Doi:10.1016/S0040-4039(02)00100-4
(2002)Doi:10.1002/ejoc.201701256
(2018)Doi:10.1016/j.tet.2004.07.041
(2004)Doi:10.1039/b107042h
(2002)Doi:10.1021/ic011035i
(2002)
